Substantiating this mechanism, murine studies with macrophage-specific deletion of myeloid differentiation primary response 88 (MyD88) demonstrated that inhibition of TLR/NF-κB-mediated macrophage inflammation significantly attenuates hepatic lipid accumulation and injury in NAFLD models [87]. Here, MYD88 is linked to metabolic dysfunction-associated steatotic liver disease.